Randy Carter
Optometrist · Salt Lake City, UTNPI 1174569990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.6% of the total.
Across 46 payments — averaging $32.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$397
- AbbVie$318
- Dompe US, Inc.$191
- Alcon$174
- Biotissue Holdings Inc.$79
- Johnson & Johnson Vision Care, Inc.$69
- plus $263 from 8 others
Across 10 payments — averaging $1149.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$11K
What the payments were for
- Food & beverage$1,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 10 | $397 |
| AbbVie(2 entities) | 11 | $318 |
| Dompe US, Inc. | 4 | $191 |
| Alcon | 3 | $174 |
| Biotissue Holdings Inc. | 3 | $79 |
| Johnson & Johnson Vision Care, Inc. | 3 | $69 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $61 |
| Coopervision Inc. | 3 | $54 |
| Hoffmann-la Roche Limited | 1 | $46 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Sight Sciences, Inc. | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,490 in reported general payments places this provider in the 65th percentile of 423 optometrist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $739,729 |
| RestasisCyclosporine | 18 | $14,533 |
| LumiganBimatoprost | 22 | $13,076 |
| Cyclosporine | 13 | $6,216 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $5,191 |
| Latanoprost | 241 | $2,644 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 170 | $1,918 |
| Fluorometholone | 15 | $1,230 |
| Prednisolone Acetate | 23 | $852 |
| Dorzolamide Hcl | 22 | $470 |
| Timolol Maleate | 43 | $348 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $224 |
| Brimonidine Tartrate | 18 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $191 | $739,72913 claims |
| AbbVieRestasis, Lumigan | $318 | $27,60940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 423 optometrist providers in Utah.
Other optometrist in Salt Lake City
- Sean CushmanSalt Lake City$25K
- Camron BatemanSalt Lake City$10K
- Karri BureshSalt Lake City$9K
- Kaeleen FransonSalt Lake City$8K
- Leidy Dayan Monsalve-WardSalt Lake City$5K
- Rick RobisonSalt Lake City$4K
- Jeffrey SimmonsSalt Lake City$4K
- Ryan GarberSalt Lake City$4K
- Christopher ValliereSalt Lake City$3K
- Stephen ReinhartHill Afb$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.